



PRINT

CLIENT: Gilead Sciences
PROJECT: ACB's Of Hep B Promo

ABCs of Hepatitis

Hepatitis means inflammation of the liver and is often caused by a virus.

There are **3** common types of viral hepatitis – each caused by a different virus.

Hepatitis A (Hep A) **Hepatitis B (Hep B)** **Hepatitis C (Hep C)**

Viral hepatitis infections can be serious diseases - people with hep B or hep C infection can progress to develop chronic liver diseases, including cirrhosis and/or liver cancer.

Understanding hepatitis starts with knowing your ABCs.

A Aware

Know your risk factors

B Blood test

Take a simple blood test to find out if you have hepatitis

C Communicate

Talk to your health care provider about hepatitis

Hep A

- You **CAN** prevent infection with a hep A vaccine.
- You **CAN** get hep A from:
 - Ingesting food or drinks contaminated with infected fecal matter
 - Being in close contact or having sexual contact with an infected person
 - Your body will usually fight off the infection, often with no lasting damage to your liver
- There is **NO** specific treatment for hep A.

Hep B

- You **CAN** prevent infection with a hep B vaccine.
- You **CAN** get hep B from:
 - Being born to an infected mother
 - Having blood-to-blood contact or sexual contact with an infected person
 - Sharing of items contaminated with infectious blood (eg, razors, toothbrushes, needles, syringes)
- You **CANNOT** get hep B from:
 - Sharing food or water
 - Touching, hugging, coughing, or kissing
- Chronic hep B is a silent killer**
Even if you don't feel sick, you can still infect others, and the virus may be active and damaging your liver. Chronic hep B can be lifelong and may cause serious liver damage, including cirrhosis and liver cancer.

Hep C

- There is **NO** vaccine available to prevent hep C.
- You **CAN** get hep C from:
 - Being born to an infected mother
 - Having blood-to-blood contact or sexual contact with an infected person
 - Sharing of items contaminated with infectious blood (eg, razors, toothbrushes, needles, syringes)
- You **CANNOT** get hep C from:
 - Sharing food or water
 - Touching, hugging, coughing, or kissing
- Chronic hep C is a silent killer**
Hep C is a slowly progressing disease with symptoms that may not appear for years, if at all. Hep C can cause serious liver damage – it is one of the leading causes of liver cancer and liver transplantation in the U.S.

To learn more about how you, your friends, and family can be screened for or manage hep B or hep C, please visit:
HepB.com and **HepCHope.com**

GILEAD GILEAD, the GILEAD Logo, HEPCHOPE, HEPB.COM, and the HEPB.COM Logo are trademarks of Gilead Sciences, Inc. ©2020 Gilead Sciences, Inc. All rights reserved. UNBC87899 1/20 **hepB.com**

Hepatitis means inflammation of the liver and is often caused by a virus.

There are **3** common types of viral hepatitis – each caused by a different virus.

Viral hepatitis infections can be serious diseases - people with hep B or hep C infection can progress to develop chronic liver diseases, including cirrhosis and/or liver cancer.

Understanding hepatitis starts with knowing your ABCs.

A Aware

Know your risk factors

B Blood test

Take a simple blood test to find out if you have hepatitis

C Communicate

Talk to your health care provider about hepatitis

Hep A

- You **CAN** prevent infection with a hep A vaccine.
- You **CAN** get hep A from:
 - Ingesting food or drinks contaminated with infected fecal matter
 - Being in close contact or having sexual contact with an infected person
 - Your body will usually fight off the infection, often with no lasting damage to your liver
- There is **NO** specific treatment for hep A.

Hep B

- You **CAN** prevent infection with a hep B vaccine.
- You **CAN** get hep B from:
 - Being born to an infected mother
 - Having blood-to-blood contact or sexual contact with an infected person
 - Sharing of items contaminated with infectious blood (eg, razors, toothbrushes, needles, syringes)
- You **CANNOT** get hep B from:
 - Sharing food or water
 - Touching, hugging, coughing, or kissing
- Chronic hep B is a silent killer**
Even if you don't feel sick, you can still infect others, and the virus may be active and damaging your liver. Chronic hep B can be lifelong and may cause serious liver damage, including cirrhosis and liver cancer.

Hep C

- There is **NO** vaccine available to prevent hep C.
- You **CAN** get hep C from:
 - Being born to an infected mother
 - Having blood-to-blood contact or sexual contact with an infected person
 - Sharing of items contaminated with infectious blood (eg, razors, toothbrushes, needles, syringes)
- You **CANNOT** get hep C from:
 - Sharing food or water
 - Touching, hugging, coughing, or kissing
- Chronic hep C is a silent killer**
Hep C is a slowly progressing disease with symptoms that may not appear for years, if at all. Hep C can cause serious liver damage – it is one of the leading causes of liver cancer and liver transplantation in the U.S.

Hep C can be cured with available treatments.

Folded Front

ABCs of Hepatitis

A Aware
Know your risk factors

B Blood test
Take a simple blood test to find out if you have hepatitis

C Communicate
Talk to your health care provider about hepatitis

Folded Back

Hepatitis means inflammation of the liver and is often caused by a virus.

There are **3** common types of viral hepatitis – each caused by a different virus.

Viral hepatitis infections can be serious diseases - people with hep B or hep C infection can progress to develop chronic liver diseases, including cirrhosis and/or liver cancer.

Understanding hepatitis starts with knowing your ABCs.

A Aware

Know your risk factors

B Blood test

Take a simple blood test to find out if you have hepatitis

C Communicate

Talk to your health care provider about hepatitis

To learn more about how you, your friends, and family can be screened for or manage hep B or hep C, please visit: **HepBSmart.com** and **HepCHope.com**

GILEAD **hepB smart!**

CLIENT: Gilead Sciences
PROJECT: Vemlidy promo pieces

CHBondemand

Clinical education from experts in hepatitis B

Educational videos related to the treatment and management of chronic hepatitis B (CHB) including:

Clinical education on hepatitis B virus (HBV) treatment and pivotal study results presented by experts in the management of CHB.

Please see our website to view more information: www.CHBondemand.com

Be sure to visit the HBV Speaker Info Hub!

Also available on www.CHBondemand.com until August 2020

Vemlidy
tenofovir alafenamide

GILEAD

Confidential - Gilead Speaker Training Use Only - Do Not Distribute

WHAT IS HEP B?

Chronic hepatitis B (hep B) is a disease caused by long-term infection by the hepatitis B virus. Over time, it can lead to serious liver damage.

It's important to know that you can't get hepatitis B from touching, kissing, drinking alcohol, food, water, air, or sharing cups and utensils.

Vemlidy
tenofovir alafenamide


GILEAD

PRINT

CLIENT: Novo Nordisk PROJECT: Ozempic Guide book

ONCE-WEEKLY
OZEMPIC®
semaglutide injection

A MODERATOR-LED DISCUSSION: Key Data from Ozempic® Glycemic Control Trials and CVOT



MODERATOR GUIDE

novo nordisk

Ozempic®
semaglutide injection

Section 2: Indication, Contraindications, and Important Safety Information

Indication and Limitations of Use¹

Ozempic® (semaglutide injection) 0.5 mg or 1 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

- Ozempic is not recommended as the first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rapid C-peptide findings to humans.
- Ozempic has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Ozempic is not a substitute for insulin. Ozempic is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis.



Important Safety Information²

WARNING: RISK OF THYROID C-CELL TUMORS

In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC). In humans, an increase in human medullary thyroid carcinoma (MTC) has not been determined.

Ozempic is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Clinical patients regarding the MTC with the use of Ozempic and reduction of exposure of thyroid cancer risk is a diagnostic, diagnosis, prevention treatment. Routine monitoring of serum calcitonin or ultrasound of thyroid gland for early detection of MTC is not recommended with Ozempic.

Contraindications:

- Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with known hypersensitivity to semaglutide or to any of the product's excipients.

Please see Important Safety Information on page 4-1.
Please see Novo Nordisk representative for Prescribing Information, including Board of Directors.
PLEASE REFER TO THE NOVO NORDISK REPRESENTATIVE OF THE COUNTRY OF THE PRODUCT.

Ozempic®
semaglutide injection

Section 3: Summary

Ozempic® - A Once-Weekly GLP-1 RA¹

SUPERIOR GLYCEMIC CONTROL vs Trulicity[®]**

SUPERIOR WEIGHT REDUCTION vs Trulicity[®]**

A 2-year CVOT demonstrated CV SAFETY with no increased risk for MACE³

Ozempic® is not indicated for weight loss⁴.

Administer once weekly, with or without meals⁵

No dose adjustments recommended in renal and hepatic impairment.

Contraindications:


- Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with known hypersensitivity to semaglutide or to any of the product's excipients.

Please see Important Safety Information on page 4-1.
Please see Novo Nordisk representative for Prescribing Information, including Board of Directors.
PLEASE REFER TO THE NOVO NORDISK REPRESENTATIVE OF THE COUNTRY OF THE PRODUCT.

Ozempic®
semaglutide injection

Section 5: Patient Case Study

Carl is a 56-Year-Old Emergency Dispatcher



Carl

Current Rx:

- Metformin (500 mg, bid)
- Lisinopril (20 mg, qd)
- Acepromorol (40 mg, qd)

Medical History:

- T2D (diagnosed ~7 years)
- ANGI (2%)
- ASCVD (MI, angina)
- Body weight ~210 lb
- MI (2012)
- HTN (130/80 mm Hg)
- CKD (Stage 2)
- Hyperlipidemia (LDL 160 mg/dL)
- LDL-C (160 mg/dL)
- MI (2012)

Lifestyle:

- Works 8-10 hours (includes an on-call emergency dispatcher working the night shift for 24 hours in a rotating on-call shift)
- Partner and grandfather both had T2D and both were treated with insulin.

Discussion Question:

- Do you believe Carl is a candidate for a GLP-1 RA? Why or why not?

Please see Important Safety Information on page 4-1.
Please see Novo Nordisk representative for Prescribing Information, including Board of Directors.
PLEASE REFER TO THE NOVO NORDISK REPRESENTATIVE OF THE COUNTRY OF THE PRODUCT.

CLIENT: Sanofi Genzyme/Regeneron
PROJECT: Dupixent invite

CLIENT: Sanofi Genzyme/Regeneron
PROJECT: Dupixent patient brochure

**PLEASE JOIN US FOR AN
Atopic Dermatitis Clinical Case Discussion**

PRESENTED BY

Jonathan Silverberg, MD, PhD, MPH
Associate Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Andrew Alexis, MD, MPH, FAAD
Professor of Dermatology
Cornell University
Ithaca, New York

DATE: Friday, April 23, 2021
Time: [start - end time] ET | [start - end time] CT | [start - end time] MT | [start - end time] PT

INDICATION: DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS: Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in 5.3% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with symptoms of adrenal insufficiency and/or adrenal crisis, which should be previously suppressed by systemic corticosteroid therapy.

Atopic Dermatitis Patients with Comorbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

ADVERSE REACTIONS: The most common adverse reactions (incidence ≥ 3% at Week 52) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 52 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS

- Pregnancy:** There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. Healthcare providers and patients may call 1-877-315-5972 or go to <https://www.dupixent.com/pregnancy-study/dupixent/> to enroll in or obtain information about the registry. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
- Lactation:** There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition. Please see accompanying full Prescribing Information.

If you have any questions regarding this program, please call p-value communications at [Phone Number].

This Industry Expert Session is a promotional activity and is not approved for continuing education credit. The content of this session and opinions expressed by presenters are those of the Presenting Company or presenters and do not represent an endorsement by, nor imply that the products have been evaluated or approved by the AAD.

This program is run independently through Regeneron and Sanofi Genzyme. CME Credit will not be earned.

SANOI GENZYME
DUPIXENT® is a registered trademark of Sanofi Biotechology
©2021 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. 04/2021 DUP21.03.02.10

REGENERON

DUPIXENT®
(dupilumab) Injection 300mg
Help Heal Your Skin From Within



INDICATION

DUPIXENT is a prescription medicine used to treat adult patients with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT.

Please see additional Important Safety Information throughout and accompanying Full Prescribing Information, including Patient Information, in the back pocket.





Gerald O'Brien

201.274.4628
go@gobriendesign.com

PRINT

CLIENT: Pace University PROJECT: Covid 19 signage

HELP KEEP PACE HEALTHY:

- Wear a mask
- Wash hands
- Use hand sanitizer
- Keep Social Distancing



PLEASE WEAR A MASK UPON ENTRY



If you don't have one, please request it from the Security




PLEASE QUE 6' APART



TWO WAY TRAFFIC!

Follow the arrow along the wall!

PRACTICE SOCIAL DISTANCING ACCORDING TO SIGNAGE!



HELP YOURSELF TO SOME HAND SANITIZER!



CLIENT: Janssen
PROJECT: Invokana promo

Make INVOKANA® Your Choice for Appropriate Adults With Type 2 Diabetes

ONLY INVOKANA® offloads ~100 GRAMS of glucose per day¹

RENAL FUNCTION remained **STABLE** with INVOKANA® over 6.5 years after an initial decline^{5,6}



The **ONLY SGLT2 INHIBITOR** with **SUPERIOR A1C** (300-mg dose), **BODY WEIGHT**, and **SBP REDUCTIONS** vs Januvia® and glimepiride with comparable overall tolerability¹⁻⁴



BEST IN CLASS ACCESS: >75% preferred* commercial and ~90% preferred Medicare Part D coverage⁷



The **FIRST-TO-MARKET** SGLT2 inhibitor with over **15 MILLION** prescriptions in the US and **LONGEST-STUDIED** with ~23,500 PATIENTS with T2DM in clinical studies^{1,5,6,8}

Make INVOKANA® Your Choice for Appropriate Adults With Type 2 Diabetes

BEST IN CLASS ACCESS: >75% preferred* commercial and ~90% preferred Medicare Part D coverage⁷

ONLY INVOKANA® offloads ~100 GRAMS of glucose per day¹

RENAL FUNCTION remained **STABLE** with INVOKANA® over 6.5 years after an initial decline^{5,6}

The **FIRST-TO-MARKET** SGLT2 inhibitor with over **15 MILLION** prescriptions in the US and **LONGEST-STUDIED** with ~23,500 PATIENTS with T2DM in clinical studies^{1,5,6,8}

The **ONLY SGLT2 INHIBITOR** with **SUPERIOR A1C** (300-mg dose), **BODY WEIGHT** and **SBP REDUCTIONS** vs Januvia® and glimepiride with comparable overall tolerability¹⁻⁴



The recommended starting dose for INVOKANA® is 100 mg once daily. INVOKANA® is not indicated for weight loss or as an antihypertensive treatment.
Please see full Prescribing Information, including Boxed WARNING, and Medication Guide available at this event.



The recommended starting dose for INVOKANA® is 100 mg once daily. INVOKANA® is not indicated for weight loss or as an antihypertensive treatment.
Please see full Prescribing Information, including Boxed WARNING, and Medication Guide available at this event.



Gerald O'Brien
201.274.4628
go@gobriendesign.com

PRINT

Virtual Event

2021 RESIDENTS' SUMMIT

May 26 - 27

Reserve una fecha para un evento educacional exclusivo para residentes! Este evento de dos días contará con palestras dos Estados Unidos e da América Latina con tradução em inglês, espanhol e português. Este evento é aberto a residentes de cirurgia e anestesiologia da América Latina.

¡Reserve la fecha para un evento educativo exclusivo para residentes! Este evento de dos días contará con oradores de todo Estados Unidos y América Latina con traducción en inglés, español y portugués. Este evento está abierto a residentes de cirugía y anestesiología de América Latina.

Para mayor información sobre este evento favor contactar a meded.latam@mmm.com.

NOTA: Este programa está dirigido exclusivamente a Profesionales de la Salud. Existe información sobre indicaciones específicas, contraindicaciones, advertencias, precauciones y seguridad con el uso de los productos y terapias de 3M-KCI. Por favor consulte las instrucciones de uso e información clínica del producto antes de utilizarlos.
Las entidades de 3M limitan la asistencia a eventos patrocinados por la empresa a profesionales de la salud con un interés profesional y de buena fe en el programa. 3M no puede pagar las comidas, refrigerios, viajes u otros gastos a los cónyuges o acompañantes de los asistentes al programa.
©Copyright 2020 3M. Todos los derechos reservados. Todas las marcas mencionadas aquí son marcas o marcas registradas propiedad de 3M. Su uso sin autorización está prohibido.
MED-MedEd-LATAM-XXXX

CLIENT: 3M-KCI PROJECT: Program invites

3M-KCI Melhores Práticas em pacientes acometidos com COVID-19

Participe dessa jornada ao cuidado do paciente tratado pela COVID-19 a partir do ponto de vista de diversos profissionais da saúde

Primeiro Módulo
11 de Maio

[Link de registro](#)

Ricardo Caio Gracco de Barreira
Medicina Interna

Hubert Oliveira Pereira
Coordenador de UCI

Segundo Módulo
09 de Junho

[Link de registro](#)

Aline Ramalho
Anestesiologia

Caral Viviana de
Medicina Clínica

Resumo do Programa

- No dia 11 de Maio, um especialista a um educador irá dar uma aula sobre o cuidado em pacientes acometidos com COVID-19
- No dia 09 de junho, a aula sobre prevenção e tratamento de sepsis por pressão será conduzida por duas enfermeiras com diferentes experiências e perspectivas
- No dia 29 de junho, especialistas mais sobre boas práticas de documentação e assistência domiciliar para os pacientes se registrarão para

3M-KCI

You are cordially invited to participate in a Summit focused on:

OPTIMIZING OUTCOMES IN CHALLENGING BREAST RECONSTRUCTION CASES - TIPS, TECHNOLOGIES AND TECHNIQUE FOR THE NEXT LEVEL.

February 21-22, 2020 | W Austin, Austin, TX

John Apostolides, MD, FACS
UPNY Plastic and Reconstructive Surgery
San Diego, California

Allen Gabriel, MD, FACS
Private Practice
Nevada, Washington

AGENDA

February 21, 2020
6:30 pm - Registration
7:00 pm - Dinner
February 22, 2020
7:00 am - 2:00 pm
Didactic Presentation
Group Conversation

PROGRAM HIGHLIGHTS:

- Discuss pre-op and post-op considerations in challenging breast reconstruction
- Review surgical techniques when managing challenging breast reconstruction
- Tips and pearls on managing complications in breast reconstruction
- Understand the importance of incision and surrounding soft tissue management in plastic surgery

AUDIENCE:
Plastic Surgeons that perform Breast Reconstruction

For more information and to register to attend, visit <https://kci.event.com/0220Dplasticcaregerysummit>
For questions about registration and program logistics, please contact the M at KCIMeetings@health.com Space is limited

3M-KCI

You are Cordially invited to Attend: Innovation Theatre at AACS

Evolving Utility of Negative Pressure Wound Therapy in Arthroplasty Patients: Review of New Clinical Evidence That May Reduce Complications and Improve Functional Outcomes

Orange County Convention Center
Innovation Theatre - Booth 1768, Hall A
Wednesday, March 25, 2020
3:15 PM - 3:35 PM

Faculty:

- Dr. John Cooper Jr., MD**
Assistant Professor of Orthopaedic Surgery
Columbia University Medical Center
New York, New York, NY
- Charles Higgins, MD**
Orthopedic Surgeon
Chief, Center for Orthopedics and Rheumatology
Department of Orthopaedic Surgery, Rehabilitation Center
Weill Cornell Medical College
New York, NY
- Timothy B. Alton, MD**
Private Practice
New York, NY

Program Objectives:

- Review recent evidence examining the importance of using negative pressure therapy for incision and surrounding tissue management
- Discuss case examples of outcomes associated with negative pressure therapy in complex arthroplasty cases
- Tips and pearls for successful outcomes in arthroplasty surgery (i.e. reducing surgical site complications and SSI)
- Take part in a question-and-answer session

Program Summary:
Please join us as we review current evidence the benefits of closed incision negative pressure therapy and present clinical outcomes associated with complex arthroplasty cases.

Walk-In Welcome For more information, visit us at Exhibit Booth #2543

CLIENT: Agile Therapeutics PROJECT: Meeting theme concept

FOCUS

Focused messaging-low estrogen (pk info- 30 vs 35, make them Opportunity- patch writers, managed care access, existing writt
Close for action, a patient type, with a sample, first line use
Use your tools: speaker programs, leadership, spec pharm, sam
Samples- be the biggest presence in the closet, establish patient

FOCUS

Focused messaging-low estrogen (pk info- 30 vs 35, make them understand) and adhesion differentiation
Opportunity- patch writers, managed care access, existing writers need to do more
Close for action, a patient type, with a sample, first line use
Use your tools: speaker programs, leadership, spec pharm, samples
Samples- be the biggest presence in the closet, establish patients on product

Agile
THERAPEUTICS

CLIENT: Sanofi Genzyme/Regeneron PROJECT: Program invite

Scales and Beyond: Assessing Different Patient Populations

Join Drs. Silverberg, Simpson, and Paller to learn how best to use disease assessment scales and additional considerations in diverse patient populations with uncontrolled atopic dermatitis.

JONATHAN SILVERBERG, MD, PhD, MPH

Feinberg School of Medicine
Northwestern University
Chicago, Illinois

ERIC SIMPSON, MD, MCR

Oregon Health & Science University
School of Medicine
Portland, Oregon

AMY PALLER, MD

Feinberg School of Medicine
Northwestern University
Chicago, Illinois

DATE
March 2, 2019

TIME
7:00 PM – 8:00 PM
(Food and beverages will be served)

LOCATION
Liberty M-P
Marriott Marquis
Washington, DC

This program is independent and is not part of the official AAD Annual Meeting as planned by its Scientific Assembly Committee. This program does not qualify for Continuing Medical Education (CME) credit.
We are unable to provide meals in connection with this event to physicians employed by the US federal government, non-US healthcare professionals or healthcare professionals holding an active medical license in Massachusetts, Minnesota, New Jersey or Vermont. In addition, spouses and other guests are not permitted to attend unless they would qualify as an appropriate attendee on their own.

© 2019 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. 012019 US ATC 199



Gerald O'Brien

201.274.4628
go@gobriendesign.com

PRESENTATION DESIGN

CLIENT: Sanofi Genzyme PROJECT: PowerPoint template design

Cerezyme® (imiglucerase)

Cerezyme has demonstrated long-term efficacy, an established safety profile, and over 20 years of real-world experience in the treatment of Gaucher disease.

Indication and usage
Cerezyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant non-neurological manifestations of the disease.

Cerezyme imiglucerase

Cerezyme's evidence is based on over 20 years of real-world experience

Multiple studies demonstrate long-term efficacy and safety

Approved by **FDA** in **1994**

Approved by **EMA** in **1997**

20+ years of real-world experience

International Collaborative Gaucher Group (ICGG) Registry

International, multicentre, longitudinal, observational patient database of **more than 6000 patients**

Open to all physicians managing Gaucher patients

Patient and physician confidentiality is strictly maintained

Program sponsored by Sanofi Genzyme

Scientific oversight provided by independent group of lysosomal storage disease specialists

Cerezyme imiglucerase

1. Cerezyme [prescribing information], Cambridge, MA, Sanofi Genzyme. 2. Cerezyme Summary of Product Characteristics (SmPC) Europe B.V. (December 2016). 3. Weisbach N et al. Am J Hematol. 2015;90(Suppl 1):S2-S5.

GD1-associated morbidity can progressively limit quality of life over time

Gaucher disease may lead to^{1,2}

- Progressive visceral enlargement, resulting in abdominal pain or distension**
- Delays in growth and puberty onset in children**
- Bone pain, osteonecrosis and fractures and impaired mobility**
- Thrombocytopenia/coagulopathy and anemia, resulting in bleeding events and/or fatigue**

Cerezyme imiglucerase

1. Mitty PK et al. Am J Hematol. 2007;82(8):697-701. 2. Cox TM. Biologics. 2010;4:299-313.

Meet Adam (9-year-old boy)

Consider the following treatment-naïve pediatric patient

- Complaint**
Fatigue
Abdominal pain
Bone pain
- History**
Easy bruising
Occasional nose bleeds
Fatigue
Growth retardation
- Exam**
Pale
Spleen 10 cm below left costal margin
Bruising on the extremities

Cerezyme imiglucerase



CLIENT: Sanofi Genzyme/Regeneron
PROJECT: PowerPoint template design

Allergist Advisory Board

DUPIXENT®
(dupilumab) Injection
200mg • 300mg

REGENERON **SANOI GENZYME**

CLIENT: SAP
PROJECT: PowerPoint template design

SAP

Implementing a Foundation for Growth
NO BORDERS, NO GLASS CEILING

CHERNO, MARCH 16, 2014

ART OF IT IS POSSIBLE



PRESENTATION DESIGN

CLIENT: Nestle PROJECT: PowerPoint template design

**ZENPEP® (pancrelipase)
Delayed-Release Capsules:
Treating Exocrine Pancreatic
Insufficiency**

Indication: ZENPEP® is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.

Nestlé HealthScience

Please see Important Safety Information for ZENPEP® within this presentation. Please see Full Prescribing Information, including Medication Guide, provided at this presentation.

ZENPEP®: Study 1

Study 1 was a Phase 3, multicenter, randomized, double-blind, placebo-controlled, two-treatment, crossover study that evaluated the safety and efficacy of ZENPEP® for the treatment of CF-associated EPI in patients ≥7 years of age.

STUDY 1^{1,2}

CF patients aged 7-23 years N=34

ZENPEP / Placebo

OPEN-LABEL Normalization Period (5-14 days)

CF = cystic fibrosis; EPI = exocrine pancreatic insufficiency.
1. ZENPEP [package insert]. Bridgewater, NJ: Nestlé HealthCare Nutrition, Inc.; March 2020. 2. Woodbridge A, et al. J Cyst Fibros. 2009;8(6):405-417.

What is ZENPEP®?

ZENPEP® is a pancreatic enzyme preparation that consists of pancrelipase, an extract obtained from porcine pancreatic glands

- Pancrelipase includes lipase, protease, and amylase
 - Lipase is the active ingredient evaluated in clinical studies of ZENPEP®
 - Additional active ingredients include protease and amylase
- Each capsule for oral administration contains enteric-coated beads
 - 1.8-1.9 mm in diameter for 3,000 and 5,000 United States Pharmacopeia (USP) units of lipase
 - 2.2-2.5 mm in diameter for 10,000, 15,000, 20,000, 25,000, and 40,000 USP units of lipase

ZENPEP [package insert]. Bridgewater, NJ: Nestlé HealthCare Nutrition, Inc.; March 2020.

ZENPEP® Dosage and Administration

- ZENPEP® is not interchangeable with other pancrelipase products
- The dosage of ZENPEP® should be individualized according to:
 - Clinical symptoms
 - Degree of steatorrhea present
 - Fat content of the diet
- ZENPEP® dosage recommendations include
 - Start at lowest recommended dose and gradually increase dose
 - Determine dose based on fat ingestion or actual body weight
 - In older patients, decrease a dose expressed as lipase units/kg of body weight per meal
 - Older patients weigh more but usually ingest less fat/kg body weight

ZENPEP [package insert]. Bridgewater, NJ: Nestlé HealthCare Nutrition, Inc.; March 2020.



CLIENT: Wyeth Nutrition PROJECT: PowerPoint template design

**5th Annual
Wyeth Nutrition
Global Summit**

**Elevating Childhood
Nutrition at Every Step**
20-21 March 2016 | Vienna, Austria

Welcome and Introductions

Professor J.B. (Hans) van Goudoever – Chair

Wyeth Nutrition

Housekeeping Notes

- Please turn off or silence all cell phones and pagers
- Please attend all sessions in their entirety
- The hospitality desk is just outside the door. The team will be pleased to assist you with any questions
- During the presentations, you may write your questions on the cards provided and hand them to a representative to give to the moderator. Microphones are also available
- Please complete your postmeeting evaluation at the end of tomorrow's session. Representatives will collect the evaluations at the doors
- The plenary room will be video recorded
- The coffee station is in the foyer

Wyeth Nutrition



Gerald O'Brien

201.274.4628


go@gobiendesign.com

PRESENTATION DESIGN


CLIENT: Omega Watches PROJECT: PowerPoint template design



CLIENT: 3M - KCI PROJECT: PowerPoint template design



CLIENT: Arena Pharmaceuticals PROJECT: PowerPoint template design






ILLUSTRATION

CLIENT: **Corcept Therapeutics**

PROJECT: Illustration showing symptoms of hypercortisolism



Overweight or Obese: 21%-48%



Myopathy: 60%-82%






Gerald O'Brien

201.274.4628
go@gobriendesign.com

ILLUSTRATION

CLIENT: **ABM Industries** PROJECT: Illustration of the company's founders



CLIENT: **Pfizer/JnJ** PROJECT: Various product illustrations




CLIENT: **Salix Pharma** PROJECT: Theme design






ILLUSTRATION

CLIENT: Salix Pharma PROJECT: Bladder cancer stages




CLIENT: LEO Pharma




CLIENT: Agile Therapeutics

PROJECT: Transdermal patch testing



CLIENT: Gilead Sciences

PROJECT: Illustration of HBV





Gerald O'Brien

201.274.4628
go@gobriendesign.com

DIGITAL DESIGN

CLIENT: **Eiasai** PROJECT: invite postcard

You're invited to attend

Exploring Data - An Immersive Experience

Saturday, December 7, 12:00 PM - 6:00 PM
Sunday, December 8, 11:00 AM - 4:00 PM
Monday, December 9, 10:00 AM - 2:00 PM

Room Pavilion B Exhibit Hall
American Epilepsy Society 2019 Annual Meeting
Baltimore Convention Center
Baltimore, MD

Eiasai

Opinions presented during this Scientific Exhibit are those of the sponsor and are not a reflection of AES opinions, nor are they supported, sponsored or endorsed by AES.
This event is only intended for full conference registered attendees only. No commercial attendees are allowed.

CLIENT: **Mallinckrodt** PROJECT: invite postcard

Understanding the Complexities of Sarcoidosis
Tuesday, October 22, 2019
10:15 AM - 11:00 AM
Learning Theater 2
Light refreshments will be provided

Speaker:
Francck Rahaghi, MD, MHS
Chairman, Department of Pulmonary and Critical Care Medicine
Director of Advanced Lung Disease Program
Director, Pulmonary Hypertension Clinic
Cleveland Clinic Florida

This program will present the medical complexities of sarcoidosis. Topics include sarcoidosis etiology, burden of disease, pathophysiology, clinical presentation, and diagnosis; advanced pulmonary sarcoidosis diagnosis and prognosis; treatment of symptomatic sarcoidosis; and unmet clinical needs. The presentation will be followed by a question-and-answer session.

A presentation at the CHEST Annual Meeting 2019, Understanding the Complexities of Sarcoidosis, is sponsored by Mallinckrodt.

This event is only intended for appropriate US healthcare professionals (HCPs). No grants or rebates of HCPs are permitted, unless they are also appropriate HCP rebates. HCPs in any of the following categories are prohibited from participating in a meal and meet either "Meal Only Card" or the "Meal Only Card" in the United States, Canada, Mexico, and Puerto Rico. Mallinckrodt Pharmaceuticals is required to report all payments or rebates (e.g., meals) in compliance with the Sunshine Act and state laws. This is a non-CME event and does not qualify for CME, CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2019 conference sessions. This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST. Only CHEST 2019 registrants can attend this symposium.

The presenter is a paid consultant of Mallinckrodt Pharmaceuticals. The content and opinions presented do not represent those of the presenter's institution.

Mallinckrodt
Pharmaceuticals

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company.
© 2019 Mallinckrodt, LLC 19101427 08/19 Printed in the USA.

CLIENT: **PharmaEssentia** PROJECT: program invite

PharmaEssentia
Better Science. Better Lives.

PharmaEssentia cordially invites you to attend a Live National Broadcast

A live discussion regarding Polycythemia Vera

DATE: March 25, 2021
TIME: 9:00 PM ET (8:00 PM CT)

FACULTY

PRESENTERS:
SRDAN VERSTOVSEK, MD, PhD
MD, Anderson Cancer Center
Houston, TX

MODERATOR:
[Name]
[Affiliation]
[City, State]

RUBEN MESA, MD
UT Health San Antonio
San Antonio, TX

Please visit
www.webcasteventregistration.com/PharmaEssentia
to register for this one-night National Event.

For additional information, please contact a p-value representative at PharmaEssentia@pvaluecomm.com or by phone at (973) 500-2071.



REAL WORLD EXPERIENCE!

OVER 78,000 PATIENTS HAVE FILLED AT LEAST 1 DUPIXENT PRESCRIPTION^{a,b}

Get the story behind our numbers at **BOOTH 4100**

DUPIXENT[®]
(dupilumab)

SANOFI GENZYME **REGENERON**

^a IQVIA National Prescription Audit (NPA) data as of [Month] (Year).
^b New patients with atopic dermatitis.
Reference: 1. Data on file, Regeneron Pharmaceuticals, Inc. AD, atopic dermatitis.

CLIENT: **Sanofi Genzyme/Regeneron**
PROJECT: Dupixent cling

CLIENT: **Nestle** PROJECT: program invite

Please Join us for a Virtual non-CME Webinar

Guidelines and Emerging Concepts in the Treatment of Chronic Pancreatitis

- Explain the mechanist definition of chronic pancreatitis and list the common etiologies
- Establish a diagnosis of chronic pancreatitis and determine the disease state
- Manage pain and exocrine pancreatic insufficiency

Date: Wednesday, January 13, 2021
Time: 4:30 PM - 6:00 PM ET

Presenters

David C. Whitcomb, MD, PhD
Giant Eagle Foundation Professor of Cancer Genetics
Professor of Medicine, Cell Biology & Molecular Physiology, and Human Genetics
Division of Gastroenterology, Hepatology and Nutrition
Director, UPMC Precision Medicine Service
University of Pittsburgh and UPMC
Editor-in-Chief, Clinical and Translational Gastroenterology
Pittsburgh, Pennsylvania

Vikesh K. Singh, MD, MSc
Associate Professor of Medicine
Director of Endoscopy, Johns Hopkins Hospital
Director, Pancreatic Center
Medical Director, Pancreatic Islet Autotransplantation Program
Division of Gastroenterology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Click or Scan to Register:
<https://cvent.me/ZQG0P1>

Nestle HealthScience



Gerald O'Brien

201.274.4628
go@gobriendesign.com

DIGITAL DESIGN

CLIENT: Sanofi Genzyme/Regeneron PROJECT: Dupixent digital banner

Do you know about DUPIXENT and how it may help your appropriate patients?

DUPIXENT®
(dupilumab)

SANOI GENZYME REGENERON

© 2019 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. DUP.19.11.0083

Visit DupixentHCP.com

CLIENT: Janssen PROJECT: Invokana digital banner

Cardiovascular Risk Reduction and Glycemic Benefits With INVOKANA®

INVOKANA®
canagliflozin tablets

CLIENT: PTC Therapeutics PROJECT: Email invite

From...	MDAConferece@mdausa.org
To...	[[Invitee Email]]
Subject	YOU'RE INVITED: Join us at our Breakfast Industry Forum at MDA on Tuesday, April 16, 2019

Please join us for an important industry forum led by expert faculty

Duchenne Muscular Dystrophy: Insights on Immunobiology and the Role of Current and Emerging Treatments

EVENT DATE & TIME:
Tuesday, April 16, 2019
6:30 AM – 6:45 AM Registration
6:45 AM – 7:45 AM Industry Forum

INDUSTRY FORUM LOCATION:
[Room Name TBD]
Hyatt Regency Orlando
9800 International Drive
Orlando, FL 32819

FACULTY:

Craig M. McDonald, MD
 UC Davis Health
 Sacramento, CA

James G. Tidball, PhD
 UCLA Brain Research Institute
 Los Angeles, CA

To RSVP, please reply via email to ptcevents@pvaluecomm.com.
Breakfast will be served.
Space is limited, so please register today.

The Forum is sponsored by PTC Therapeutics, Inc.
For further inquiries, please email ptcevents@pvaluecomm.com

PTC THERAPEUTICS
measured by moments

CLIENT: PharmaEssentia PROJECT: Registration

PharmaEssentia cordially invites you to attend a National Broadcast

A live discussion and Q&A regarding Polycythemia Vera

PharmaEssentia National Broadcast

Select this event
PharmaEssentia National Broadcast 1
Date: March 25, 2021
Time: 6:00pm - 7:00pm EDT

Select this event
PharmaEssentia National Broadcast 2
Date: March 25, 2021
Time: 9:00pm - 11:00pm EDT

If you're already registered for the PharmaEssentia National Broadcast, click below:

ALREADY REGISTERED?

SPEAKERS

Ruben Mesa, MD
 UT Health San Antonio
 San Antonio, TX

Srdan Verstovsek, MD, PhD
 MD Anderson Cancer Center
 Houston, TX

MODERATOR

Ray Urbanski, MD, PhD
 Head of Medical Affairs and Clinical Development, PharmaEssentia

Register for the selected events

First Name

Last Name

Email Address

City

State/Prov

Zip

Country

NPI #

Registration Type

If Other, please explain:

Specialty

I have read and agree to the [terms of use](#) and [privacy policy](#).

ENTER

© 2021 PharmaEssentia Corporation. All rights reserved. PharmaEssentia is a trademark of PharmaEssentia Corporation. [US Registration job Code.]

PharmaEssentia

Privacy Policy | Port Troubleshooting | System Check | Technical Requirements | Term of Use



Gerald O'Brien

201.274.4628

go@gobriendesign.com

DIGITAL DESIGN

CLIENT: BMS

PROJECT: Zeposia email invite

CLIENT: Sanofi Gynzyme

PROJECT: Cerdelga email invite

CLIENT: Janssen

PROJECT: Cerdelga email invite

LIVE WEBINAR

once-daily ZEPOSIA (ozanimod)

PLEASE JOIN US FOR A PRESENTATION ON:
ZEPOSIA® (ozanimod) for the Treatment of Relapsing Forms of Multiple Sclerosis

Webinar Information
Date: Wednesday, August 12, 2020
Time: 7:00pm EST

Please click the URL below to register for this Webinar Program:
https://event.webcasts.com/starthere.jsp?ei=1348618&ip_key=033478619a
(U.S. residents only)

If internet access is not available, please use our dial-in number:
877-407-5795 / 201-689-8722
(U.S. residents only)

For technical support: 877-407-0626 or 201-689-7835

Please click "Download Document" below to see the full Zeposia (ozanimod) Important Safety Information, Prescribing Information, and Medication Guide

Speaker:
Robert Shin, MD
Georgetown University Hospital
Washington, DC

This event is sponsored by Bristol Myers Squibb and speakers are paid consultants of Bristol Myers Squibb. This material was developed and approved for the U.S. audience only.

COMSN
The aim of this program is to explore the use of the ZEPOSIA (ozanimod) for the Treatment of Relapsing Forms of Multiple Sclerosis, to include Clinically Isolated Syndrome, Relapsing-Remitting Disease, and Active Secondary Progressive Disease, in Adults

Objectives:

- Overview of ZEPOSIA including S1P receptor expression and function, mechanisms of action, and dosing and administration
- Discuss the clinical trials for ZEPOSIA including clinical trial design, efficacy, and safety
- Explore the patient support services program

Don't miss this great opportunity!

COMSN | info.comsn.org | www.comsn.org

© 2020 Bristol Myers Squibb Company. 06/2020 US_ZEP-20-0712

SAVE THE DATE

A Virtual Symposium on Gaucher Disease
A Comprehensive Case for Cerdelga

Please join Dr. Heather Lau and globally renowned panels of Gaucher disease experts for two premier events

Webinar 1	Webinar 2
October 27, 2020 11:00 AM – 1:30 PM EST	November 6, 2020 7:00 AM – 9:30 AM EST

Heather Lau, MD
Assistant Professor, Department of Neurology at NYU Grossman School of Medicine
Associate Director, Division of Neurogenetics
Director, Lysosomal Storage Disease Program
NYU Langone Health
New York, New York, USA

Cerdelga is indicated for the long-term treatment of adult patients with GD1, who are CYP2D6 poor metabolizers (PM), intermediate metabolizers (IM) or extensive metabolizers (EM).

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This meeting is organized and sponsored by
SANOFI GENZYME

MAT-GLB-2001679-v1.0-08/2020

To: [HCP Name]
From: "Janssen Pharmaceuticals, Inc." (Email TBD)
Subject: Join Us for an Engaging Virtual Discussion

Please join us for an engaging virtual discussion
The Science of Fatigue in Multiple Sclerosis

REGISTER NOW

Join us for a discussion on MS fatigue including its pathophysiology.

SPEAKERS:

Joseph R. Berger, MD
Professor of Neurology and Associate Chief of the MS Division
University of Pennsylvania
Philadelphia, PA

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York

This educational activity is brought to you by Janssen Pharmaceuticals, Inc. and is not certified for continuing medical education. The consultants are paid faculty for Janssen Pharmaceuticals, Inc. The faculty are presenting on behalf of Janssen and must present information in compliance with FDA requirements applicable to Janssen.

Thursday, December 3, 2020

12:30pm EST 11:30am CST 10:30am MST 9:30am PST REGISTER NOW	3:30pm EST 2:30pm CST 1:30pm MST 12:30pm PST REGISTER NOW	8:30pm EST 7:30pm CST 6:30pm MST 5:30pm PST REGISTER NOW
--	--	---

Please read our [Privacy Policy](#)
If you wish to unsubscribe, [please click here](#).

This email was sent by: Janssen Pharmaceuticals, Inc.
1125 Trenton-Harbourton Road, Titusville, NJ 08950 USA
© Janssen Pharmaceuticals, Inc. 2020 10/20 cp-192487v1

CLIENT: Castle Creek Pharm PROJECT: Email

ARE YOU OR YOUR CHILD SUFFERING FROM EBS?

LEARN MORE ABOUT THE DELIVERS STUDY

The DELIVERS study will look at the safety and efficacy of the investigational compound, DELIVERS, in children for the treatment of Duchenne's muscular dystrophy.

TO PARTICIPATE IN THE STUDY, YOU MUST MEET THESE CRITERIA:

- All ages 5 years of age
- Duchenne's muscular dystrophy, confirmed by genetic testing
- No other disease affecting the nervous system
- No use of any drugs, supplements, or vitamins within 30 days of enrollment
- No other conditions

With the help of the DELIVERS study, we can learn more about the safety and efficacy of the investigational compound, DELIVERS, in children for the treatment of Duchenne's muscular dystrophy.

DELIVERS EBS

CLICK HERE for more information about the DELIVERS study, including a list of participating centers and the correct information, or you can call **1-877-DELIVERS.COM**

CLIENT: PTC Therapeutics PROJECT: Splash page

Duchenne Muscular Dystrophy: Insights on Immunobiology and the Role of Current and Emerging Treatments

April 15, 2019

LEARN MORE

PTC





Gerald O'Brien

201.274.4628
go@gobriendesign.com

LOGO DESIGN


ADSC ALLIANCE DERMATOLOGY STEERING COMMITTEE

REGENERON
SANOFI GENZYME

CLIENT: Sanofi Genzyme/Regeneron PROJECT: Conference logo



CLIENT: PharmaHEALTH Labs
PROJECT: Conference logo



CLIENT: Corcept PROJECT: Conference logo




CLIENT: Northstar Comm
PROJECT: Conference logo



CLIENT: Endo Pharmaceutical
PROJECT: Conference logo



CLIENT: Endo Pharmaceutical PROJECT: Conference logo



CLIENT: iconectiv
PROJECT: Corporate logo



CLIENT: RAD
PROJECT: Corporate logo



WEB

CLIENT: Agile Therapeutics
PROJECT: Corporate website



CLIENT: Napo Pharmaceuticals
PROJECT: Mytesi product website



CLIENT: Johnson and Johnson
PROJECT: RD&E global website





Gerald O'Brien

201.274.4628

go@gobriendesign.com

WEB

CLIENT: DMJ Studios

PROJECT: Corporate website

516.300.1500 | info@dmjstudios.net

Leverage Video Increase Donations Build your Following

DMJ Studios has collaborated with our clients to help raise over 100 million dollars for a wide range of trusted non-profits. Let's collaborate, strategize, and create a winning campaign together.

CREATE VIDEO WITH IMPACT!

DMJ Studios has been producing videos for social media, broadcast, corporate and non-profits for over two decades, with stunning results.

CREATIVE STRATEGY

From social media videos to virtual events, we're your partners in furthering your cause.

VIDEO PRODUCTION

From insurance or trade presentations, from grants to donors, we're the right team for the right project.

POST PRODUCTION

With decades of research experience, our editors, animators and strategists together bring all of the audio, video, motion graphics, and more, together with the most beautiful sound design.

Create Branded Content on budget and on time

Tell Us Your BIG Plans!

What type of video do you need?

Corporate

Name *

First Last

Email *

Comment or Message *

Submit

A FEW OF OUR CLIENTS

- Virtual events and gala videos
- Attracting and retaining your donor base
- Marketing and promoting your next event
- Touching hearts with compelling stories
- Organization overview
- Testimonials

- Social media videos to engage donors all year
- Honoree biographies to keep your audience engaged
- Animated explainers
- Building your team and volunteers
- Website, featured in newsletters

Our Clients are OUR BEST Advertising

DEREK SAKER
Director of Communications OHel Family Services

"Internally we think of ideas, then we take them to DMJ, and DMJ always raises the bar and gives us even better ideas."

ABOUT US

Result-driven Video Agency since 1992. Maximize your ROI with our powerful concept to completion approach.

SERVICES

- Our Work
- About
- Our Team
- Career Opportunities
- News
- Services
- Contact
- Call 516.300.1500

CONTACT US

409 Central Avenue, 2nd floor
Cedarhurst, NY 11516
212.874.5073
516.300.1500
info@dmjstudios.net

[Y](#) [T](#) [F](#) [I](#) [N](#)

Copyright © 2021, DMJ Studios.

CLIENT: Reliable Machinery

PROJECT: Corporate website

RELIABLE MACHINERY & PLASTIC PUNCH PRESS

OVER 75 YEARS OF EXPERIENCE COMMITTED TO EXCELLENCE

Corporate Website Design | Logo & Brand | Regular

HOME ABOUT SUPPLY RANGE CONTACTS TRAFFIC ANALYTICS DONORS

THE NEW 1000 SERIES

1000 Series Punch Press

1000 Series Punch Press

1000 SERIES

1000 Series Punch Press

1000 Series Punch Press

1000 SERIES

1000 Series Punch Press

1000 Series Punch Press

© 2021 Reliable Machinery. All rights reserved.



CLIENT: SironRX

PROJECT: Corporate website

Home Technology Press Room Team Contact Us Log In

SironRX THERAPEUTICS

Enhanced dermal wound healing using the body's own repair processes

SironRX Therapeutics is a private clinical-stage company developing novel therapies for dermal wound repair with a specific focus on mitigating scar formation and accelerating wound healing. Through its lead product, JVS-100, SironRX is targeting these indications with significant market potential and high-unmet medical need.

JVS-100 is a clinically tested, non-viral DNA plasmid that encodes stromal cell-derived factor 1 (SDF-1). SDF-1 is naturally produced by the human body in response to tissue injury and activates the body's own native repair processes, recruiting endogenous stem cells to the damaged region and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved across tissue types.

SironRX is currently enrolling in a double-blind, placebo-controlled, randomized clinical trial in surgical wounds. The Company is evaluating JVS-100 drug safety and its ability to reduce scar formation and accelerate wound repair. Previous clinical studies with JVS-100 have demonstrated the drug is well tolerated and safe.

Copyright © 2023, SironRX Therapeutics. All rights reserved.



Gerald O'Brien

201.274.4628

go@gobriendesign.com

INTERACTIVE

CLIENT: Novo Nordisk

PROJECT: Interface program

CLIENT: Corcept Therapeutics

PROJECT: Interface program



CLIENT: Pfizer

PROJECT: Global index of Innovator Award winners



Gerald O'Brien

201.274.4628
go@gobriendesign.com

LARGE FORMAT PRINT



CLIENT: Sanofi Genzyme/Regeneron PROJECT: Dupixent conference graphics

CLIENT: iconectiv PROJECT: Murals for corp headquarters



mission

We enable the interconnection of networks, devices, and applications for more than one billion people every day.
We know the world of tomorrow is counting on us, and we are delivering.

vision

We imagine a world without boundaries, where the ability to access and exchange information is simple, secure and seamless.
SIMPLE We make the systems and processes that are extraordinarily complex, comprehensible
SEAMLESS We simplify information exchange, on a global scale, and make it instantly available
SECURE We are trusted with the critical data that makes the world run





Gerald O'Brien

201.274.4628

go@gobriendesign.com

LARGE FORMAT PRINT

CLIENT: Pace University PROJECT: Gym Mural



CLIENT: Credit Suisse PROJECT: Office wall murals





CLIENT: Port Authority of NY & NJ

PROJECT: Floor clings



CLIENT: Port Authority of NY & NJ

PROJECT: Music area murals/clings







Gerald O'Brien

201.274.4628
go@gobriendesign.com

3D DESIGN

CLIENT: Agile Therapeutics PROJECT: New product concepts (Twirla packaging)





Gerald O'Brien

201.274.4628

go@gobriendesign.com

ANIMATION, MOTION DESIGN & VIDEO

CLIENT: **SAP**

PROJECT: Subtly moving animated video background



CLIENT: **HPE**

PROJECT: Subtly moving animated video background



CLIENT: **Pfizer** PROJECT: Promo video

